A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients by De Vita, F et al.
A phase II study of biweekly oxaliplatin plus infusional
5-fluorouracil and folinic acid (FOLFOX-4) as first-line
treatment of advanced gastric cancer patients
F De Vita*,1, M Orditura
1, E Matano
2, R Bianco
2, C Carlomagno
2, S Infusino
2, V Damiano
2, E Simeone
2,
MR Diadema
1, E Lieto
3, P Castellano
3, S Pepe
2, S De Placido
2, G Galizia
3, N Di Martino
4, F Ciardiello
1,
G Catalano
1 and AR Bianco
2
1Division of Medical Oncology, ‘F Magrassi & A Lanzara’ Department of Clinical and Experimental Medicine, Second University of Naples School of
Medicine, Naples, Italy;
2Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, ‘Federico II’ University of
Naples School of Medicine, Naples, Italy;
3II Division of General Surgery, ‘F Magrassi & A Lanzara’ Department of Clinical and Experimental Medicine,
Second University of Naples School of Medicine, Naples, Italy;
4VII Division of General Surgery, ‘F Magrassi & A Lanzara’ Department of Clinical and
Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional
5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer
(AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85mgm
 2 on day 1, FA 200mgm
 2 as a 2h
infusion followed by bolus 5-FU 400mgm
 2 and a 22h infusion of 5-FU 600mgm
 2, repeated for 2 consecutive days every 2 weeks.
All patients were assessable for toxicity and response to treatment. Four (7%) complete responses and 19 partial responses were
observed (overall response rate, 38%). Stable disease was observed in 22 (36%) patients, with progressive disease in the other six
(10%) patients. Median time to progression (TTP) and median overall survival (OS) were 7.1 and 11.2 months, respectively. National
Cancer Institute Common Toxicity Criteria grade 3 and 4 haematologic toxicities were neutropenia, anaemia and thrombocytopenia
in 36, 10 and 5% of the patients, respectively. Grade 3 peripheral neuropathy was recorded in three (5%) patients. FOLFOX-4 is an
active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based
regimens, suggesting a role for this combination in gastric cancer.
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Despite a decreasing trend in its incidence, gastric cancer remains
the second most common cause of cancer-related death (Parkin,
1998); furthermore, there was a change in the site of origin within
the stomach, with a rising incidence of cancer of cardia and
gastroesophageal junction (Blot et al, 1991). Advanced gastric
cancer (AGC) remains incurable with a median survival of 6–9
months (Alberts et al, 2003). However, in randomised trials,
chemotherapy was demonstrated to result in both a significant
survival advantage and an improved quality of life when compared
to best supportive care (Murad et al, 1993; Pyrhonen et al, 1995;
Glimelius et al, 1997). 5-Fluorouracil (5-FU) remains the most
extensively studied single agent, and continuous intravenous
infusion is frequently used in combination chemotherapy regi-
mens (Alberts et al, 2003). The association of epirubicin, cisplatin
and 5-FU in continuous infusion, also known as ECF regimen,
showed an impressive activity in a phase II trial, with 12%
complete responses (CR). Compared with FAMTX in a phase III
randomised trial, ECF obtained a higher response rate, a superior
median time to progression (TTP) and a better overall survival
(OS) (Webb et al, 1997). Because of these results, ECF was
considered as the European standard treatment. Several platinum
analogues have been developed with the aim of improving the
efficacy and tolerability of cisplatin. Recently, oxaliplatin, a third-
generation platinum compound with the 1,2-diaminocyclohexane
(DACH) carrier ligand, has entered the clinical practice, showing a
different toxicity profile, with neurotoxicity being the dose-
limiting toxicity (Extra et al, 1990; Raymond et al, 1998).
Oxaliplatin showed additive or synergistic activity when associated
to 5-FU, even in 5-FU-resistant cell lines (Becouarn et al, 2001). It
has been registered worldwide for the treatment of advanced
colorectal cancer, where, in association with 5-FU, it was reported
to yield a response rate of 36–58% (Levi et al, 1992; Levi et al,
1994; De Gramont et al, 2000). In in vitro studies, oxaliplatin was
demonstrated to inhibit the growth of several gastric cancer cell
lines (Eriguchi et al, 2003). In a phase II study involving previously
CDDP-treated patients with AGC, a bimonthly association of
Revised 5 January 2005; accepted 11 March 2005; published online 26
April 2005
*Correspondence: Dr F De Vita, Division of Medical Oncology, ‘F
Magrassi & A Lanzara’ Department of Clinical and Experimental
Medicine, Second University of Naples School of Medicine, c/o II
Policlinico, Via S Pansini, 5, 80131 Naples, Italy;
E-mail: fernandodevita@yahoo.it
British Journal of Cancer (2005) 92, 1644–1649
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
soxaliplatin, 5-FU and leucovorin was associated with a 26% RR and
an acceptable toxicity profile (Kim et al, 2003). Furthermore, in a
phase II study, a biweekly FOLFOX-6 regimen (oxaliplatin
100mgm
 2, FA 400mgm
 2 followed by bolus 5-FU 400mgm
 2
and a 46h continuous infusion of 5-FU 3000mgm
 2) was
demonstrated to be an active and safe treatment in 51
chemotherapy-naive patients with AGC (Louvet et al, 2002). These
results were recently extended by a multicentre phase II study in
41 AGC patients treated with a modified FOLFOX schedule
(oxaliplatin 85mgm
 2, FA 500mgm
 2 followed by 5-FU
2600mgm
 2 as a 24h continuous infusion every 2 weeks) (Al-
Batran et al, 2004). Here, we report the results of a multicentre
phase II trial aimed at determining the efficacy and safety of a
FOLFOX-4 regimen as first-line treatment in 61 AGC patients.
PATIENTS AND METHODS
Eligibility
Patients with histologically proven unresectable locally advanced
or metastatic gastric cancer were considered eligible for the study
if they met all of the following criteria: measurable disease;
cytologically or histologically proven single metastatic lesion as the
only manifestation of the disease; aged 418 and o75 years; ECOG
PS o2; life expectancy 43 months; adequate bone marrow,
hepatic and renal function; no prior palliative chemotherapy;
written informed consent before enrolment in the study. Previous
adjuvant chemotherapy was allowed if more than 6 months had
elapsed between the end of adjuvant therapy and first relapse.
Treatment and toxicity assessment
Chemotherapy consisted of oxaliplatin 85mgm
 2 on day 1, FA
200mgm
 2 as a 2h infusion followed by bolus 5-FU 400mgm
 2
and a 22h infusion of 5-FU 600mgm
 2 on days 1 and 2 every 2
weeks. The use of central venous catheters and disposable pumps
allowed chemotherapy administration on an outpatient basis. This
regimen was administered until progression. Toxicity was assessed
before starting and each 2-week cycle using the National Cancer
Institute Common Toxicity Criteria (NCI-CTC), version 1.0, except
neurotoxicity. Peripheral sensitive neuropathy was graded accord-
ing to the following oxaliplatin-specific scale: grade 1, paresthesias/
hypoesthesias of short duration with complete recovery before the
next cycle; grade 2, paresthesias/hypoesthesias persisting between
two cycles without functional impairment; grade 3, permanent
paresthesias/hypoesthesias resulting in functional impairment
(Caussanel et al, 1990). Treatment delays and dose modifications
were based on the worst adverse effects observed during the
previous cycle. Oxaliplatin was reduced to 75mgm
 2 in case of
persistent (414 days) paresthesia or temporary (7–14 day)
painful paresthesia or functional impairment. In case of persistent
(414 days) painful paresthesia or functional impairment,
oxaliplatin was omitted from the treatment until recovery.
Together with reductions in the dose of oxaliplatin, the bolus
dose of 5-FU was reduced to 300mgm
 2 and the infusion dose to
500mgm
 2 in the event of grade 3 or 4 neutropenia, thrombo-
cytopenia, diarrhoea, stomatitis or other drug-related adverse
effects of grade 3. Treatment was delayed by up to 3 weeks until the
patient recovered from various adverse effects, the neutrophil
count exceeded 1500 per cubic millimetre and the platelet count
exceeded 100000 per cubic millimetre. In the event of skin toxicity
of grade 3 or 4, only the dose of 5-FU was reduced.
Study end points
In 4 weeks before starting chemotherapy, all patients underwent
the following studies: physical examination, complete blood cell
count, hepatic and renal function tests, chest and abdominal CT
scan and an ultrasound endoscopy. Physical examination, hepato-
renal function tests and blood counts were performed every cycle.
Tumour evaluation was assessed every three cycles according to
WHO criteria. Complete response is defined as the disappearance
of all known lesions and absence of new lesions; partial response
(PR) as a reduction of 50% or more in the sum of the product of
the two-dimensional measures of all known lesions and absence
of new lesions; stable disease (SD) as a reduction of o50% or an
increase o25% in the sum of the product of the two-dimensional
measures of all known lesions and absence of new lesions; and
progressive disease (PD) as an increase of 425% in the two-
dimensional measures of one or more known lesions or as the
appearance of at least one new lesion. Treatment was continued
until disease progression or unacceptable toxicity occurred or until
a patient chose to discontinue treatment. All patients who
completed at least three cycles of chemotherapy were deemed
assessable for response. All eligible patients were included in the
response and survival analysis on an ‘intent-to-treat’ basis. The
primary end point of the study was the overall response rate;
secondary end points were toxicity, evaluation of TTP and OS.
Statistical analysis
The two-stage minimax design for phase II trial of Simon (1989)
was adopted, selecting an alpha error¼0.05 and a beta
error¼0.20. The minimum activity required for this experimental
treatment was 30%, while the alternative hypothesis was to obtain
a 50% response rate. Therefore, the accrual had to be stopped if
less than six responses were obtained with the first 16 patients.
Otherwise, more than 18 responses among a total of 46 patients are
required to accept this hypothesis.
Statistical analysis was carried out using the BMDP statistical
package (BMDP Statistical Software Inc., Los Angeles, CA, USA).
In all analyses, the significance level was specified as Po0.05. The
Kaplan–Meier method was used to analyse TTP and OS.
RESULTS
Patient characteristics
A total of 61 patients were enrolled from March 2001 to June 2003.
The characteristics of the patients are summarised in Table 1. The
median age was 64 years and the majority of patients had a
Performance Status 1 according to the ECOG scale. A G3
undifferentiated tumour was present in 31 patients (51%), while
a G2 moderately differentiated tumour was observed in 28 patients
(46%). Metastatic disease was present in the majority of the study
population (56 out of 61 patients); liver (38 out of 61 patients,
62%) and lymph nodes (25 out of 61 patients, 36%) were the most
common sites of metastases. The median number of organs
involved was two (range, 1–4), with 27 patients (44%) having two
organs involved, 10 patients (16%) having three organs involved
and two patients (3%) having four organs involved. Prior surgery
was performed in 37 out of 61 patients. No patient had received
prior radiotherapy, while 10 patients had received adjuvant
chemotherapy with 5-FU and folinic acid according to the
Machover regimen following radical surgery.
Tumour response
All 61 patients were evaluable for response to therapy. Major
responses were observed in 23 patients (38%; 95% CI, 25.8–50.2),
with four patients achieving a CR (7%) and 19 showing a PR
(31%). One CR was pathologically confirmed, since the patient
underwent curative surgery after nine cycles of chemotherapy and
was alive without evidence of disease as of 31 December 2003.
Stable disease was obtained in 22 additional patients (36%).
Progressive disease was observed in 16 patients (26%). Therefore,
FOLFOX-4 in advanced gastric cancer
F De Vita et al
1645
British Journal of Cancer (2005) 92(9), 1644–1649 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthe overall tumour growth control (CRþPRþSD) was 74% (45
out of 61 patients).
Survival
All patients were included in the survival analysis on an intent-to-
treat basis. The median follow-up was 11.6 months (range, 6.9–
20.3 months). The median TTP was 7.1 months (95% CI, 5.6–8.7)
(Figure 1). At the time of analysis (31 December 2003), 44 patients
had died and 17 were alive. The median OS was 11.2 months (95%
CI, 9.66–14.39). At the time of analysis, two patients who achieved
a CR were disease free at 19.9 and 7.6 months of follow-up,
respectively. Following documentation of disease progression, 36
out of 61 patients received a second-line docetaxel- or irinotecan-
based chemotherapy. As shown in Figure 2, patients receiving a
second-line treatment had a statistically significant (P¼0.0026;
long-rank test) longer median OS (12.7 months; 95% CI, 10.7–15.6)
than patients (25 patients) receiving only best supportive care
(median OS, 9.4 months; 95% CI, 5.6–12.7).
Toxicity
A total of 450 cycles were administered, with a median of seven
cycles for patients (range, 3–15 cycles). A total of 45 out of 61
patients (74%) received at least six cycles, 34 out of 61 patients
(56%) received at least eight cycles and 14 out of 61 patients (23%)
received at least 10 cycles. The occurrence and the incidence of
main toxicities are reported in Table 2. The most common
toxicities were haematologic. The National Cancer Institute
Common Toxicity Criteria grade 3 and 4 neutropenia, leucopenia,
Table 1 Patient characteristics
No. of patients (n¼61) %
Sex
Male 38 62
Female 23 38
Age (years)
Median 64
Range 47–75
Histologic diagnosis
Adenocarcinoma 55 90
Signet ring cell carcinoma 6 10
Grading
12 3
22 8 4 6
33 1 5 1
Performance status
09 1 5
13 9 6 4
21 3 2 1
Adjuvant chemotherapy
Yes 10 16
No 51 84
Disease status
Locally advanced 5 8
Metastatic 56 92
No. of organs involved
12 2 3 6
22 7 4 4
31 0 1 6
432 3
Organs involved
Liver 38
Lung 12
Nodes 25
Peritoneum 13
Pleura 23
Ovaries 1
Pancreas 2
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Figure 2 Estimated 21-month cumulative probability of survival in 61
AGC patients. Shown are OS in the 36 AGC patients treated with second-
line chemotherapy (&&&&&&) and in the 25 patients treated with
best supportive care (JJJJJ) following disease progression. The
figure also depicts OS in the 61 patients (’’’’’).
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Figure 1 Estimated 21-month cumulative probability of survival and time
to treatment progression in 61 AGC patients. Shown are TTP
(&&&&&&) and OS (’’’’’) in the 61 AGC patients treated
with the FOLFOX-4 regimen.
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sanaemia and thrombocytopenia were recorded in 22 out of 61
(36%), 11 out of 61 (16%), six out of 61 (10%) and three out of 61
(5%) patients, respectively. Three out of 61 patients experienced
febrile neutropenia. No NCI-CTC grade 4 gastrointestinal toxicity
was observed, while grade 3 diarrhoea, nausea and vomiting were
recorded in 5, 5 and 2% of the patients, respectively. Neurotoxicity
was moderate and was observed in 30% (grade 1 in 11%, grade 2 in
14% and grade 3 in 5%) of the patients. The three patients who
experienced a grade 3 neurotoxicity received a dose of oxaliplatin
ranging from 935 to 1275mgm
 2 and cycles from 11 to 15. Three
patients (5%) discontinued treatment because of treatment-related
side effects, specifically neutropenia (one patient), diarrhoea (one
patient) and neurotoxicity (one patient). No treatment-related
death was reported.
DISCUSSION
Although gastric cancer is considered a relatively chemotherapy-
sensitive tumour with an overall response rate ranging between 30
and 60%, survival of AGC patients remains unsatisfactory, with a
median survival time of 6–9 months (Ho et al, 1988; Kelsen et al,
2002). None of the current regimens can be considered as an
optimal therapy for AGC and new therapeutic strategies are needed
to achieve a better clinical efficacy with an acceptable toxicity
profile. In the present study, we administered the combination of
FA, 5-FU and oxaliplatin as first-line therapy to patients with AGC.
In all, 23 of 61 (38%) patients achieved an objective response, with
a 7% CR rate. The overall median TTP was 7.14 months, with a
median OS of 11.2 months. The results of this study confirm the
activity of a biweekly FOLFOX-4 regimen in the first-line treatment
of AGC patients. To our knowledge, this is the largest phase II
study in this patient population. Indeed, the other two phase II
trials of oxaliplatin, 5-FU and FA combination in chemotherapy-
naive AGC patients enrolled 54 (49 patients were assessable for
response) and 41 (37 patients were assessable for response)
patients, respectively (Louvet et al, 2002; Al-Batran et al, 2004).
Table 3 summarises the results of our study in comparison with
the two previously published phase II trials of oxaliplatin, FA and
5-FU as first-line therapy in AGC patients. RR was comparable in
the three studies. However, the median TTP and OS in the present
study were slightly better than those reported in the other two
studies. The prolonged survival observed in our study cannot be
related to a selected patient population with a good outcome,
because 56 out of 61 (92%) patients had a metastatic disease and
63% had at least two metastatic sites. On the contrary, it could be
explained by the fact that 59% of the study population received a
second-line therapy. In fact, the 36 patients receiving a second-line
treatment with docetaxel or irinotecan had a significant better
median OS than the 25 patients receiving only best supportive care
(12.7 vs 9.4 months; P¼0.0026). These data suggest that salvage
chemotherapy in AGC patients progressing after a first-line
treatment may have a beneficial impact on survival, as has also
been shown in other reports (Ajani et al, 2002; Giuliani et al, 2003).
As previously observed in advanced colorectal cancer, in AGC
patients, the FOLFOX regimen used in this study demonstrated an
acceptable tolerability. Grade 3/4 neutropenia was the most
Table 2 Main toxicities according to NCI-CTC scale
Toxicity Grade 1–2 (%) Grade 3–4 (%)
Haematologic
Neutropenia 14 (23) 22 (36)
Leucopenia 11 (18) 12 (19)
Thrombocytopenia 20 (32) 3 (5)
Anaemia 23 (37) 6 (10)
Febrile neutropenia — 2 (3)
Gastrointestinal
Nausea 13 (21) 3 (5)
Vomiting 12 (19) 1 (2)
Diarrhoea 14 (23) 3 (5)
Stomatitis 7 (11) 1 (2)
Hepatic 1 (2) —
Neurological
a 16 (26) 3 (5)
Others
Cutaneous 1 (2) —
Alopecia 12 (19) —
Asthenia 13 (21) 1 (2)
Allergic 2 (3) —
aAccording to an oxaliplatin-specific scale (grade 0–3).
Table 3 Comparison of the published phase II studies using FOLFOX combinations as first-line chemotherapy in AGC patients
Study
No. of
evaluable
patients %RR (%CR)
Median TTP
(mo)
Median OS
(mo)
NCI-CTC
G1–G2
toxicities (%)
NCI-CTC
G3–G4
toxicities (%)
G1–G2
neurotoxicity (%)
a
G3 neurotoxicity
(%)
a
Louvet et al (2002) 49 45 (4) 6.2 8.6 Neutropenia
(30)
Neutropenia
(38)
66 21
Leucopenia
(43)
Leucopenia
(19)
Anaemia (80) Anaemia (11)
Al-Batran et al
(2004)
37 43 (3) 5.6 9.6 Anaemia (51) Anaemia (7) 39 0
Diarrhoea (37) Diarrhoea (7)
Neutropenia
(12)
Neutropenia
(5)
De Vita et al (2004)
(this report)
61 38 (7) 7.14 11.2
b Neutropenia
(23)
Neutropenia
(36)
26 5
Leucopenia
(18)
Leucopenia
(16)
Anaemia (37) Anaemia (10)
aAccording to an oxaliplatin-specific scale (grade 0–3).
bOverall survival was 12.74 months in 36 out of 61 patients receiving a second-line chemotherapy and 9.46 months in 25
out of 61 patients treated with best supportive care following disease progression. AGC¼advanced gastric cancer; CR¼complete response; TTP¼time to progression;
OS¼overall survival; mo¼months.
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scommon haematologic toxicity occurring in 36% of the patients,
but febrile neutropenia was detected in only 3% of the patients.
In a number of trials with oxaliplatin-based therapies, neuro-
toxicity was the most frequent side effect that led to treatment
discontinuation. However, in our study, neurotoxicity was
restricted to a limited number of patients. This may be due to a
relatively low cumulative dose of oxaliplatin in our series, with a
median number of seven cycles administered. In particular, in the
study by Louvet et al (2002), in which oxaliplatin was administered
at a dose of 100mgm
 2, peripheral neuropathy was reported in
87% of the treated population and was severe (grade 3 toxicity) in
21% of the patients. In our series, diarrhoea, nausea and vomiting
were the most common side effects among nonhaematologic
toxicities, but were mild and occurred less frequently when
compared with CDDP-based regimens such as FUP and ECF (Kim
et al, 1993; Webb et al, 1997). Similarly, alopecia was a rare side
effect when compared with anthracyclines or etoposide-based
regimens. The efficacy of this FOLFOX treatment was not different
from that observed in phase II–III studies with other second- or
third-generation polychemotherapy regimens in AGC (Lacave
et al, 1991; Wils et al, 1991; Kelsen et al, 1992; Kim et al 1993;
Rougier et al, 1994; Vanhoefer et al, 2000). Interestingly, the
median TTP and OS observed in our study population are similar
to those reported in a prospectively randomised study comparing
ECF with the standard regimen FAMTX (Webb et al, 1997). In
conclusion, FOLFOX-4 treatment appears to have a significant
activity as first-line treatment for AGC patients, with an
encouraging response rate and a mild toxicity profile; therefore,
on the basis of these results, a phase III study comparing FOLFOX-
4 vs ECF should be performed.
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